Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06873204 · ClinicalTrials.gov registry record · NA
Impact of Soluble Arabinoxylan and Rice Bran Fiber on the Gut Microbiome in Healthy Adults
A NA study, sponsored by Purdue University.
- Not yet
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT06873204: Clinical Trial NA study, sponsored by Purdue University.
NCT06873204 is a NA study that has not yet begun recruiting, run by Purdue University. The registered enrollment target is 25 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06873204, a NA study, has not yet begun recruiting, sponsored by Purdue University.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
The importance of the gut microbiota for general health has been recently elucidated, but little is known about the impact of different types of nutrients on the gut microbiota. The soluble fiber in cereal by-products, arabinoxylan (AX), is known to be beneficial for generally promoting gut health. However, it is unclear whether consuming rice bran (RB), the source of AX, is equally helpful or better than consuming the extracted form of AX. This study aims to reveal the potential benefit of insoluble cereal bran fiber ingredients by comparing the effect of soluble arabinoxylan fiber alone and the mostly insoluble rice bran fiber, containing arabinoxylan, on intestinal health and gut microbiota. A placebo (maltodextrin) will be used as a control, with no significant changes expected in this group for the evaluated outcomes. Participants will: * Consume two different fiber supplements (soluble arabinoxylan or stabilized rice bran) as well as a placebo (maltodextrin) for 3 weeks each, separated by a 2-week washout period. * Provide blood and stool samples at six different time points. * Complete a food and gastrointestinal symptom diary during the intervention periods.
Primary Outcome
The primary outcome of the study is change in butyrogenic Clostridium cluster XIVa gut bacteria.
Interventions
- DIETARY_SUPPLEMENT Maltodextrin (Placebo)
- DIETARY_SUPPLEMENT Soluble Arabinoxylan
- DIETARY_SUPPLEMENT Rice Bran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2025-07 |
| Est. Completion | 2025-10 |
| Phase | NA |
What is known before NCT06873204 opens enrollment
NCT06873204 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Maltodextrin (Placebo) is the first listed.
NCT06873204 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06873204 about?
NCT06873204 is a clinical study titled "Impact of Soluble Arabinoxylan and Rice Bran Fiber on the Gut Microbiome in Healthy Adults". The importance of the gut microbiota for general health has been recently elucidated, but little is known about the impact of different types of nutrients on the gut microbiota. The soluble fiber in cereal by-products, arabinoxylan (AX), is known to be beneficial for generally promoting gut health. ...
What is the current status of trial NCT06873204?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 25 participants. The study started on 2025-07. Estimated completion is 2025-10.
What interventions are being tested in trial NCT06873204?
The interventions under investigation include: Maltodextrin (Placebo) (DIETARY_SUPPLEMENT), Soluble Arabinoxylan (DIETARY_SUPPLEMENT), Rice Bran (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06873204?
This trial is sponsored by Purdue University, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06873204's enrollment target sits among peer trials
25 1712th of 2000 higher than 265 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia